UK Markets close in 6 hrs 40 mins

Vascular Disrupting Agents Market, 2030

·5-min read

Dublin, July 14, 2021 (GLOBE NEWSWIRE) -- The "Vascular Disrupting Agents Market, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions" report has been added to ResearchAndMarkets.com's offering.

The 'Vascular Disrupting Agents Market, 2021-2030 report features an extensive study of the current and future potential of vascular disrupting agents, being developed for the treatment of various types of cancer. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade.

Presently, there are multiple small molecule VDAs, which have been / are being developed for the treatment of a variety of oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma and ovarian cancer. Moreover, combination therapies, involving VDAs and conventional chemotherapy, radiation therapy and radioimmunotherapy, have demonstrated excellent clinical responses in multiple animal models.

It is worth noting that the R&D efforts in this field are being supported by the National Institutes of Health, accounting for USD 95 million in research grants disbursed since 2016. Driven by encouraging clinical research, this niche, but emerging domain, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with vascular disrupting agents, over the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2021-2030.

Key Questions Answered

  • Who are the leading industry and non-industry players in this market?

  • Which cancer indications can be treated with vascular disrupting agents?

  • Which geographies are the most active in conducting clinical trials on vascular disrupting agents?

  • What is the focus area of the research activities ongoing in this domain?

  • Which are the leading administering institute centers supporting the research related to this domain?

  • Who are the key opinion leaders that can help you drive your development efforts?

  • How is the current and future market opportunity likely to be distributed across key market

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Vascular Disrupting Agents
3.2.1. Mechanism of Action of Vascular Disrupting Agents
3.3 Types of Vascular Disrupting Agents
3.3.1. Small Molecule Vascular Disrupting Agents
3.3.1.1. Tubulin Binding Agents
3.3.1.2. Flavonoids
3.3.2. Ligand Directed Vascular Disrupting Agents
3.4. Benefits of Vascular Disrupting Agents
3.5. Challenges Associated with Vascular Disrupting Agents
3.6. Future Perspectives

4. VASCULAR DISRUPTING AGENTS MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Vascular Disrupting Agents: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Target Disease Indication
4.2.4. Analysis by Phase of Development and Target Disease Indication
4.2.5. Analysis by Type of Molecule
4.2.6. Analysis by Target Disease Indication and Type of Molecule
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Potential Combination Therapeutics
4.3. Vascular Disrupting Agents: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Players: Analysis by Number of Drug Candidates

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AGC Biologics
5.3. Avid Bioservices
5.4. Bionomics
5.5. Mateon Therapeutics
5.6. Myrexis
5.7. VBL Therapeutics

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Vascular Disrupting Agents: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Trial Status
6.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.4. Analysis by Trial Phase
6.3.5. Analysis by Trial Phase and Number of Patients Enrolled
6.3.6. Geographical Analysis by Number of Clinical Trials
6.3.7. Geographical Analysis by Number of Patients Enrolled
6.3.8. Analysis by Study Design
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Drug Molecule
6.3.11. Analysis by Key Indications
6.3.12. Analysis by Type of Sponsor/Collaborator
6.3.13. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.14. Most Active Non-Industry Players: Analysis by Number of Registered Trials

7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Vascular Disrupting Agents: List of Recent Publications

8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Vascular Disrupting agents: Academic Grants Analysis

9. KOL ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Methodology
9.3. Principal Investigators of Vascular Disrupting Agents Focused Clinical Trials
9.3.1. Geographical Distribution of KOLs
9.3.2. Analysis by Type of Organization (KOL Affiliation)
9.3.3. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
9.4. Prominent Key Opinion Leaders (KOLs)
9.5. KOL Benchmarking: Publisher versus Third-Party Scoring (ResearchGate Score)
9.6. Profiles of Most Active KOLs

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Key Assumptions and Forecast Methodology
10.4. Overall Vascular Disrupting Agents Market, 2021-2030
10.4.7. Product-wise Sales Forecast
10.4.7.1. Bavituximab (Avid Bioservices)
10.4.7.2. Icaritin (Beijing Shenogen Biomedical)
10.4.7.3. NGR-TNF (AGC Biologics)
10.4.7.4. Padeliporfin (Steba biotech)
10.4.7.5. Plinabulin (BeyondSpring Pharmaceuticals)
10.4.7.6. VB-111 (VBL Therapeutics)

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/wxwc2m

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting